FibroBiologics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 16.49 million compared to USD 5.12 million a year ago. Basic loss per share from continuing operations was USD 0.68 compared to USD 0.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.09 USD | -20.26% | -24.19% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 370M | |
+16.73% | 121B | |
+13.04% | 107B | |
-5.80% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.00% | 15.31B | |
+1.18% | 14.08B | |
+24.18% | 11.74B |
- Stock Market
- Equities
- FBLG Stock
- News FibroBiologics, Inc.
- FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023